Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 121

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 121
---
em Ordinary Shares and the future business and financial results of NLS and Kadimastem; •The Merger is subject to the satisfaction or waiver of conditions that may not be satisfied or completed on a timely basis, if at all. Failure to consummate the Merger could adversely affect the future business and financial results of NLS; •NLS will have limited protection in the event that any of the representations and warranties made by Kadimastem ultimately proves to be inaccurate or incorrect; •Lawsuits may be commenced seeking to enjoin or prevent the Merger or seeking other relief which may delay or prevent the completion of the Merger and result in NLS or Kadimastem incurring substantial costs; and •The Merger may proceed despite material adverse changes, and if its benefits fall short of market expectations, NLS’s share price could decline. These risks and other risks are discussed in greater detail under the section entitled “Risk Factors” in this proxy statement/prospectus. Nasdaq Capital Market Listing (see page 161) NLS has filed a listing of additional securities application with Nasdaq, as required by Nasdaq to effect the issuance of NLS Common Shares in connection with the Merger or upon exercise of options or warrants or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares that will be assumed by NLS in connection with the Merger. If such application is accepted, NLS anticipates that its securities will be listed on the Nasdaq Capital Market following the Closing, and subject to approval of Proposals1,2,4,6,8, 13 and 14 in the NLS Meeting, will trade under NLS’s new name, NUCLEX AG. Anticipated Accounting Treatment (Pages 161) The most recent financial information available for NLS for twelve months ended December 31, 2024 has been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP. The most recent financial information available for Kadimastem for the twelve months ended December 31, 2024 has been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Boards, or IASB. The Merger is anticipated to be accounted for using the acquisition method (as a reverse triangular merger), with goodwill and other identifiable intangible assets recorded in accordance with IFRS, as applicable to be determined at the time of Merger.